Finoriq research workspace
Roivant Sciences Ltd. (ROIV) Historical Metrics
In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform. Review ROIV valuation ratios, fundamentals, and filing metrics on Finoriq.
Company Snapshot
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
- Company
- Roivant Sciences Ltd. (ROIV)
- Ticker
- ROIV
- Market Cap
- $24.7B
- Latest Price
- $34.28
- Industry
- Biotech & Pharma
Roivant Sciences Ltd. (ROIV) Current Valuation Metrics
Static valuation preview for Roivant Sciences Ltd. (ROIV). Market data retrieved 2026-07-08. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/SMarket cap divided by latest TTM revenue. | 3,144x | Revenue | TTM FY 2026 |
| Earnings YieldLatest TTM net income divided by market cap. | -1.2% | Net Income | TTM FY 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -2.9% | Operating Cash Flow | TTM FY 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 5.74x | Stockholders' Equity | FY 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.